Knockdown of PIK3R6 impedes the onset and advancement of clear cell renal cell carcinoma

References

• Bukavina L, Bensalah K, Bray F, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82(5):529–542. doi: 10.1016/j.eururo.2022.08.019
   PubMed Web of Science ®Google Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and Testicular tumours. Eur Urol. 2016;70(1):93–105. doi: 10.1016/j.eururo.2016.02.029
   PubMed Web of Science ®Google Scholar
• Jiang Z, Chu PG, Woda BA, et al. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res. 2008;14(17):5579–5584. doi: 10.1158/1078-0432.CCR-08-0504
   PubMed Web of Science ®Google Scholar
• Eggener SE, Yossepowitch O, Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006;24(19):3101–3106. doi: 10.1200/JCO.2005.04.8280
   PubMed Web of Science ®Google Scholar
• Sciarra A, Gentile V, Salciccia S, et al. New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. Rev Recent Clin Trials. 2008;3(2):97–103. doi: 10.2174/157488708784223808
   PubMedGoogle Scholar
• Zhang H, Ma M. Circ_0101692 knockdown retards the development of clear cell renal cell carcinoma through miR-384/FN1 pathway. Transl Oncol. 2023;28:101612. doi: 10.1016/j.tranon.2022.101612
   PubMed Web of Science ®Google Scholar
• Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7–24. doi: 10.1038/nrc3860
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329–341. doi: 10.1038/nrm2882
   PubMed Web of Science ®Google Scholar
• Li J, Kaneda MM, Ma J, et al. PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. Proc Natl Acad Sci USA. 2021;118(16):118. doi: 10.1073/pnas.2009290118
   Web of Science ®Google Scholar
• Xu Y, Afify SM, Du J, et al. The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells. Sci Rep. 2022;12(1):347. doi: 10.1038/s41598-021-04265-w
   PubMed Web of Science ®Google Scholar
• Becattini B, Breasson L, Sardi C, et al. PI3Kγ promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation. JHEP Rep. 2021;3(6):100359. doi: 10.1016/j.jhepr.2021.100359
   PubMedGoogle Scholar
• Wang X, Huang S, Xin X, et al. The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ. Acta Pharm. 2019;69(1):111–119. doi: 10.2478/acph-2019-0004
   PubMed Web of Science ®Google Scholar
• Liu YJ, Cui LL, Liu ZS, et al. RBBP6 aggravates the progression of ovarian cancer by targeting PIK3R6. Eur Rev Med Pharmacol Sci. 2020;24(20):10366–10374. doi: 10.26355/eurrev_202010_23386
   PubMed Web of Science ®Google Scholar
• Du Y, Zhao W, Han H, et al. PIK3R6 promotes angiogenesis in hepatocellular carcinoma by activating STAT3 signaling pathway. Altern Ther Health Med. 2023;29(8):704–709.
   PubMed Web of Science ®Google Scholar
• Liu M, Liao L, Gao Y, et al. BCAM deficiency May contribute to preeclampsia by suppressing the PIK3R6/p-STAT3 signaling. Hypertension. 2022;79(12):2830–2842. doi: 10.1161/HYPERTENSIONAHA.122.20085
   PubMed Web of Science ®Google Scholar
• Lee MJ, Jin N, Grandis JR, et al. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochim Biophys Acta, Mol Cell Res. 2020;1867(6):118679. doi: 10.1016/j.bbamcr.2020.118679
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 2016;6(10):1090–1105. doi: 10.1158/2159-8290.CD-16-0716
   PubMed Web of Science ®Google Scholar
• Liu X, Xu Y, Zhou Q, et al. PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. Future Oncol. 2018;14(7):665–674. doi: 10.2217/fon-2017-0588
   PubMed Web of Science ®Google Scholar
• Kobialka P, Sabata H, Vilalta O, et al. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib. EMBO Mol Med. 2022;14(7):e15619. doi: 10.15252/emmm.202115619
   PubMed Web of Science ®Google Scholar
• Hopkins BD, Pauli C, Du X, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560(7719):499–503. doi: 10.1038/s41586-018-0343-4
   PubMed Web of Science ®Google Scholar
• Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273–291. doi: 10.1038/nrclinonc.2018.28
   PubMed Web of Science ®Google Scholar
• Tang SW, Chang WH, Su YC, et al. MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett. 2009;273(1):35–43. doi: 10.1016/j.canlet.2008.07.038
   PubMed Web of Science ®Google Scholar
• Helsten T, Kato S, Schwaederle M, et al. Cell-cycle gene alterations in 4,864 tumors analyzed by next-generation sequencing: implications for targeted therapeutics. Mol Cancer Ther. 2016;15(7):1682–1690. doi: 10.1158/1535-7163.MCT-16-0071
   PubMed Web of Science ®Google Scholar
• Kõivomägi M, Swaffer MP, Turner JJ, et al. G1cyclin–cdk promotes cell cycle entry through localized phosphorylation of RNA polymerase II. Science. 2021;374(6565):347–351. doi: 10.1126/science.aba5186
   PubMed Web of Science ®Google Scholar
• Sun F, Li N, Tong X, et al. Ara-c induces cell cycle G1/S arrest by inducing upregulation of the INK4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4/cyclin D1. Cell Cycle. 2019;18(18):2293–2306. doi: 10.1080/15384101.2019.1644913
   PubMed Web of Science ®Google Scholar
• Xu H, He L, Feng X, et al. Specific reduction of fas-associated protein with death domain (FADD) in clear cell renal cell carcinoma. Cancer Invest. 2009;27(8):836–843. doi: 10.1080/07357900902849681
   PubMed Web of Science ®Google Scholar
• Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009;122(4):437–441. doi: 10.1242/jcs.031682
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi: 10.1158/2159-8290.CD-21-1059
   PubMed Web of Science ®Google Scholar
• Zhao J, Dong D, Sun L, et al. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer. Int Braz J Urol. 2014;40(2):179–189. doi: 10.1590/S1677-5538.IBJU.2014.02.07
   PubMed Web of Science ®Google Scholar
• Yuan M, Zou X, Liu S, et al. Modified jian-pi-yang-zheng decoction inhibits gastric cancer progression via the macrophage immune checkpoint PI3Kgamma. Biomed Pharmacother. 2020;129:110440. doi: 10.1016/j.biopha.2020.110440
   PubMed Web of Science ®Google Scholar
• Fan D, Liu Q, Wu F, et al. Prognostic significance of PI3K/AKT/mTOR signaling pathway members in clear cell renal cell carcinoma. PeerJ. 2020;8:e9261. doi: 10.7717/peerj.9261
   PubMed Web of Science ®Google Scholar
• Chen L, Qing J, Xiao Y, et al. TIM-1 promotes proliferation and metastasis, and inhibits apoptosis, in cervical cancer through the PI3K/AKT/p53 pathway. BMC Cancer. 2022;22(1):370. doi: 10.1186/s12885-022-09386-7
   PubMed Web of Science ®Google Scholar